Antiangiogenic tomor therapies have attracted intense interest for their broad-spectrum action, low toxicity, and in the case of direct endothelial targeting, an absence of drug resistance. Among the growing list of antiangiogenic agents, endostatin has attracted most attention and been under the spotlight of numerous debates. Like other angiogenesis inhibitors, endostatin is also a proteolytic fragment (~20 kDa) from an extracellular protein, collagen XVIII. It potently inhibits endothelial cell proliferation and angiogenesis, but has no cytotoxic effects on cancer cells. Above all, therapy of experimental cancer with endostatin in rodents leads to tumor dormancy and does not induce resistance. However, the exact mechanism on how endostatin inhibited endothelial cells proliferation remains largely unknown. We have cloned mouse endostatin cDNA from mice liver by RT-PCR. After verification by DNA sequencing, endostatin cDNA was subcloned in to E.coli expression vector to express and generate large quantities of recombinant GST-fused endostatin (GST-endostatin). Unlike His-tagged endostatin, GST-endostatin is soluble and capable of inhibiting various endothelial cell lines including HUVEC, EA.hy926 and BAEC with IC50 ~ 20 nM. Flow cytometry analysis indicated GST-endostatin induced apoptosis in EA.hy926 cells. GST-endostatin also inhibited the cell migration of EA.hy926 cells toward chemoattractant bFGF with IC50 ~ 0.5 nM. Further more, GST-endostatin inhibited in vivo angiogenesis in chicken chorioallantoic membrane and suppressed tumor growth in mice bearing Lewis lung carcinoma cells. After functional characterization of GST-endostatin, we decided to use GST-endostatin and EA.hy926 cells as a model system to study the inhibitory mechanism of endostatin in endothelial cells. By using fura-2 fluorescence probe, GST-endostatin was shown to elevate the cytosolic calcium in dose-dependent manner from extracellular source. Chelation of extracellular Ca2+ by EGTA or inhibition of calcium channel by nifedipine abolished the cytotoxic effect endostatin, suggesting the calcium rise by endostatin play an important role in its inhibitory mechanism. Besides, endostatin also stimulated activity of a large- conductance calcium-activated potassium (Bkca) channel, further supporting endostatin initiated serial changes in ion channels activities in endothelial cells. Respiratory enzyme activities and endogenous ATP synthesis in endothelial cells were significantly inhibited by GST-endostatin treatment, indicating GST-endostatin depleted the energy source for endothelial cells. In summary, present study demonstrated GST-endostatin caused dramatic changes in electrophysiologic properties and decreased endogenous ATP synthesis in endothelial cells, which may participate in its inhibitory mechanism.

University, Diss., 2003--Köln.

Abstract Angiogenesis is essential for the replacement of cartilage by bone during skeletal growth and regeneration. Vascular endothelial growth factor-A (VEGF-A) is a key regulator of angiogenesis whereas endostatin, a potent inhibitor of endothelial cell proliferation and migration, is a natural antagonist of VEGF-A. The regulatory roles of these peptides in angiogenesis, bone formation and bone cells were investigated in this study. In the present work we studied the effects of VEGF-A, delivered with an adenoviral vector, on the recovery of bone drilling defects in rat femur. Our data confirm the important role of VEGF in bone healing and that adenoviral VEGF gene transfer may modify bone defect healing in a rodent model. We studied the effects of VEGF-A and endostatin on bone resorption activity. It was found that VEGF-A is a potent stimulator of bone resorption and osteoclast differentiation in vitro and endostatin can antagonize this stimulatory effect when acting directly on bone cells. This suggests that endostatin is indeed a regulator of bone resorption, but not a critical one. In the present study we induced ectopic bone formation in the hamstring muscles of adult mice. The effects of VEGF-A and endostatin in the ectopic bone formation assay were evaluated by the simultaneous delivery of both peptides with recombinant adenoviral vectors. It was found that endostatin retards the cartilage phase in endochondral ossification that subsequently reduces bone formation. We conclude that bone growth and healing, which share features with ectopic bone formation, may be regulated by endostatin. To confirm in vivo effects on bone formation we further investigated the effects of endostatin and VEGF-A on mouse pre-osteoblastic cells in vitro. Finally the effects of endostatin on bone were studied in transgenic mouse lines overexpressing endostatin, and mice lacking collagen XVIII.

Endostatin, an angiogensis inhibitor, was discovered by Dr. Judah Folkman¡¦s group in 1997. From their series studies, they demonstrated that the angiogenesis inhibition approach, which abolished the formation of new blood vessels and led to starvation of cancer cells, is a safe, effective anticancer method without side effect and drug resistance. Phase clinical trial on endostatin was carried out in 1999 and completed in 2001, heralding the approaching of a new arsenal of cancer therapy drugs. Endostatin is also a proteolytic fragment (~20 kDa) from an extracellular protein, collagen XVIII. It potently inhibits endothelial cell proliferation and angiogenesis, but has no cytotoxic effects on other cells. Above all, cycled therapy of experimental cancer in rodents with endostatin led to tumor dormancy without drug resistance. However, the exact mechanism on how endostatin inhibited endothelial cells proliferation remains largely unknown. We have cloned mouse endostatin cDNA from mice liver by RT-PCR. After verification by DNA sequencing, endostatin cDNA was subcloned in to E. coli expression vector to express and generate large quantities of recombinant GST-fused endostatin. Unlike His-tagged endostatin, GST-endostatin is soluble and capable of inhibiting endothelial cell lines EA.hy926 with a half-maximal inhibition concentration (IC50) of 20 nM. In present study, we investigated whether GST-endostatin caused alterations in cytoskeleton in endothelial cells. By using a fluorescence dye to visualize the actin filament under confocal microscope, it was found that endostatin induced the corruption of actin network in endothelial cells. Western blot analysis revealed that GST-endostatin treatment caused downregulation of cytoskeleton proteins such as tubulin, vimentin and ECM-related signaling molecules such as focal adhesion kinase (FAK), mitogen activated protein kinse (MAPK), Erk in a dose-dependent manner. Moreover, GST-endostatin decreased the levels of cell survival factor such as AKT and NF-£eB. Since GST-endostatin induced sustained calcium rise, the effect of endostatin on protein kinase Cs (PKCs) were studied and revealed that endostatin reduced the levels of PKCK1¡BPKC eta¡BPKC iota and PKC lamda. Other than endothelial cell, the cytotoxicity of GST-endostatin in hepatoma cells were investigated since liver the primary expression site of collagen XVIII, precursor of endostatin. Unexpectedly, endostatin also inhibited the proliferation of hepatoma cells. Flow cytometry and nucleus staining indicated that GST-endostatin also induced apoptosis in hepatoma cells. Moreover, GST-endostatin exhibited differential cytotoxic effect against well-differentiated (such as HepG2, Hep3B) and poor differentiated (such as Mahlavu, Sk-hep-1) hepatoma cells that the IC50 for well differentiated hepatoma cells were 8-10 folds lower than for poor-differentiated cells. Above all, GST-endostatin inhibited the migration of SK-hep-1 and modulated the secretion of matrix-metalloproteinases (MMPs) by Mahlavu and SK-hep-1 cells. In summary, present study explored the role of alterations in cytoskeleon network in the cytotoxic mechanism of GST-endostatin. Moreover, the inhibitory effects of GST-endostatin on proliferation of hepatoma cells were reported for the first time.

Made available in DSpace on 2014-10-09T12:35:31Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:04:02Z (GMT). No. of bitstreams: 0 / Tese (Doutoramento) / IPEN/T / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

Made available in DSpace on 2014-10-09T12:35:31Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:04:02Z (GMT). No. of bitstreams: 0 / Tese (Doutoramento) / IPEN/T / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

Orientador: Fábio Porto-Foresti / Resumo: Os pesticidas organofosforados, como por exemplo o diclorvós (DDVP), são amplamente utilizados na atualidade, apesar de existirem muitos estudos que comprovem a sua atuação como desreguladores endócrinos. Esses desreguladores são capazes de interferir na homeostase mantida pelos hormônios e podem estar ligados ao desenvolvimento de lesões neoplásicas no sistema genital masculino, como o câncer de próstata, que representa a segunda maior incidência de neoplasias no sexo masculino no mundo. A progressão dessas lesões pode se dar através do processo de angiogênese e depende do equilíbrio local nas atividades de fatores proangiogênicos e antiangiogênicos. Um dos fatores antiangiogênicos mais bem estudados é a endostatina, inibidor endógeno da angiogênese, enquanto que o fator proangiogênico mais importante é o VEGF, juntamente com o seu receptor Flk-1. A angiogênese pode ser induzida pela hipóxia que ocorre no ambiente tumoral devido à disponibilidade limitada de oxigênio entre as células proliferativas. Assim, o presente estudo teve como objetivo analisar a morfologia e os marcadores moleculares envolvidos no processo de angiogênese (HIF-1α, VEGF, Flk-1 e endostatina) na próstata de ratos para avaliar a influência do praguicida diclorvós, associado ou não à indução química por N-metil-N-nitrosoureia (MNU). Foram utilizados 32 ratos da linhagem Fischer 344, com idade de 90 dias. Os ratos foram separados em quatro grupos experimentais: Controle, DDVP, MNU, MNU+DDVP. Foram feitas a... (Resumo completo, clicar acesso eletrônico abaixo) / Mestre

A terapia gênica tem sido empregada em estudos pré-clínicos e clínicos, com o intuito de amenizar ou curar uma doença. Vetores retrovirais são uma ferramenta de transferência gênica largamente utilizada. Vetores bicistrônicos são uma alternativa interessante para o tratamento de doenças complexas. Na construção de um vetor bicistrônico pode-se empregar várias estratégias dentre elas a utilização da sequência IRES. A endostatina, fragmento do colágeno XVIII, tem sido muito utilizada na terapia anti-angiogênica devido sua ação inibitória no crescimento de células endoteliais. A imunoterapia tem sido utilizada como tratamento coadjuvante de tumores. Dentre as citocinas utilizadas, a interleucina-2 promovendo a proliferação de linfócitos T, tem sido utilizada em diversos estudos pré-clínicos e clínicos. O objetivo deste projeto foi construir e caracterizar in vitro um vetor retroviral bicistrônico codificando endostatina e interleucina-2 utlizando a sequência IRES. A construção do vetor foi realizada em três etapas, sendo comprovada a construção final por análise de restrição e seqüenciamento. Células de empacotamento foram transfectadas com o vetor, e posteriormente realizada a transdução na célula alvo. A endostatina e a interleucina-2 foram determinadas por Dot blot, seguido de análise da expressão por RT-PCR e ensaio de atividade. O vetor construído apresentou altos níveis de titulação viral, variando de 4.20x105 a 1.53x106UFC/mL. A determinação da endostatina e da interleucina-2 variaram entre 1.08 a 2.08g/106cels.24h e 0.66 a 0.89μg/106cels.24h, respectivamente. A expressão da endostatina no clone NIH3T3-pLend-IRES-IL2SN foi 2 vezes superior á apresentada pelo clone NIH3T3-pLend-IRES-IL2SN. A endostatina produzida promoveu uma inibição da proliferação de 40% das células endoteliais; e a interleucina-2 promoveu uma proliferação de 10.6% de linfócitos CD4 e 8.9% de CD8. Desta forma, a construção obtida neste trabalho representa uma excelente ferramenta para estudos da biologia celular do câncer e novas estratégias terapêuticas. / Gene therapy has been used in preclinical studies and clinical trials in order to alleviate or cure a disease. Retroviral vectors are a tool for gene transfer is widely used. Bicistronic vectors are an attractive alternative for treatment of complex diseases. A variety of options exists to simultaneously express two genes in genetically modified cells. The most common approach relies on bicistronic vectors in which the genes are linked to each other by an internal ribosome entry site allowing co-translational expression of both cistrons. Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. At present, ES has been widely used in anti-angiogenic in a variety of experimental tumor models, and clinical trials to test it as an anti-tumor agent are already under way. Immunotherapy has been used as adjuvant treatment for tumors and has been used in several preclinical studies and clinical trials. The objective of this project was to construct and characterize in vitro an IRES-based bicistronic retroviral vector encoding endostatin and intereukin-2. The construction of the vector was performed in three stages, the final construction was analyzed by restriction analysis and sequencing. Packaging cells were prepared. The endostatin and interleukin-2 levels were determined by Dot blot. Monocistronic and bicistronic mRNA expression were analyzed by real time RT-PCR. Bicistronic vector showed high levels of virus trites, ranging from 4.20x105 to 1.53x106UFC/mL. Secreted levels of endostatin and interleukin-2 ranged from 1.08 to 2.08μg/106cells.24h and 0.66 - 0.89g/106cells.24h, respectively. The mRNA expression of ES in the NIH3T3 clone pLend-IRES-IL2SN was 2 times higher than the level presented by the NIH3T3 clone pLendSN. The endostatin promoted inhibition (40%) of endothelial cell proliferation. Interleukin-2 promoted a proliferation of 10.6% lymphocytes CD4 and 8.9% of CD8. We conclude that the IRES bicistronic vector provides a powerful tool for studies of cell biology of cancer and new therapeutic strategies.

A terapia gênica tem sido empregada em estudos pré-clínicos e clínicos, com o intuito de amenizar ou curar uma doença. Vetores retrovirais são uma ferramenta de transferência gênica largamente utilizada. Vetores bicistrônicos são uma alternativa interessante para o tratamento de doenças complexas. Na construção de um vetor bicistrônico pode-se empregar várias estratégias dentre elas a utilização da sequência IRES. A endostatina, fragmento do colágeno XVIII, tem sido muito utilizada na terapia anti-angiogênica devido sua ação inibitória no crescimento de células endoteliais. A imunoterapia tem sido utilizada como tratamento coadjuvante de tumores. Dentre as citocinas utilizadas, a interleucina-2 promovendo a proliferação de linfócitos T, tem sido utilizada em diversos estudos pré-clínicos e clínicos. O objetivo deste projeto foi construir e caracterizar in vitro um vetor retroviral bicistrônico codificando endostatina e interleucina-2 utlizando a sequência IRES. A construção do vetor foi realizada em três etapas, sendo comprovada a construção final por análise de restrição e seqüenciamento. Células de empacotamento foram transfectadas com o vetor, e posteriormente realizada a transdução na célula alvo. A endostatina e a interleucina-2 foram determinadas por Dot blot, seguido de análise da expressão por RT-PCR e ensaio de atividade. O vetor construído apresentou altos níveis de titulação viral, variando de 4.20x105 a 1.53x106UFC/mL. A determinação da endostatina e da interleucina-2 variaram entre 1.08 a 2.08g/106cels.24h e 0.66 a 0.89μg/106cels.24h, respectivamente. A expressão da endostatina no clone NIH3T3-pLend-IRES-IL2SN foi 2 vezes superior á apresentada pelo clone NIH3T3-pLend-IRES-IL2SN. A endostatina produzida promoveu uma inibição da proliferação de 40% das células endoteliais; e a interleucina-2 promoveu uma proliferação de 10.6% de linfócitos CD4 e 8.9% de CD8. Desta forma, a construção obtida neste trabalho representa uma excelente ferramenta para estudos da biologia celular do câncer e novas estratégias terapêuticas. / Gene therapy has been used in preclinical studies and clinical trials in order to alleviate or cure a disease. Retroviral vectors are a tool for gene transfer is widely used. Bicistronic vectors are an attractive alternative for treatment of complex diseases. A variety of options exists to simultaneously express two genes in genetically modified cells. The most common approach relies on bicistronic vectors in which the genes are linked to each other by an internal ribosome entry site allowing co-translational expression of both cistrons. Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. At present, ES has been widely used in anti-angiogenic in a variety of experimental tumor models, and clinical trials to test it as an anti-tumor agent are already under way. Immunotherapy has been used as adjuvant treatment for tumors and has been used in several preclinical studies and clinical trials. The objective of this project was to construct and characterize in vitro an IRES-based bicistronic retroviral vector encoding endostatin and intereukin-2. The construction of the vector was performed in three stages, the final construction was analyzed by restriction analysis and sequencing. Packaging cells were prepared. The endostatin and interleukin-2 levels were determined by Dot blot. Monocistronic and bicistronic mRNA expression were analyzed by real time RT-PCR. Bicistronic vector showed high levels of virus trites, ranging from 4.20x105 to 1.53x106UFC/mL. Secreted levels of endostatin and interleukin-2 ranged from 1.08 to 2.08μg/106cells.24h and 0.66 - 0.89g/106cells.24h, respectively. The mRNA expression of ES in the NIH3T3 clone pLend-IRES-IL2SN was 2 times higher than the level presented by the NIH3T3 clone pLendSN. The endostatin promoted inhibition (40%) of endothelial cell proliferation. Interleukin-2 promoted a proliferation of 10.6% lymphocytes CD4 and 8.9% of CD8. We conclude that the IRES bicistronic vector provides a powerful tool for studies of cell biology of cancer and new therapeutic strategies.

A síndrome de Knobloch (SK) é uma doença autossômica recessiva rara, caracterizada por problemas oculares e presença de encefalocele occipital, porém o quadro clínico é variável. Os pacientes apresentam principalmente miopia de grau elevado, degeneração vítreo-retiniana e descolamento de retina; o grau de comprometimento da alteração no occipital também é variável. Nossos estudos mostraram que a SK é causada por mutações no gene COL18A1, que codifica o colágeno tipo XVIII. Esse colágeno, uma proteoglicana da matriz extracelular, tem sido estudado principalmente por liberar a endostatina, um fragmento de 20 kDa clivado proteoliticamente de sua porção C-terminal e que possui atividade inibidora da angiogênese. O colágeno XVIII possui três isoformas conhecidas, as quais diferem entre si apenas na porção N-terminal e apresentam padrões de expressão distintos nos tecidos, mesmo estando ubiquamente presentes nas membranas basais epiteliais e endoteliais. Além da endostatina, o colágeno XVIII apresenta outros motivos com funções ainda desconhecidas: um domínio trombospondina, presente em todas as isoformas e um domínio frizzled, encontrado apenas na forma mais longa da proteína. O espectro de variação clinica na SK ainda é incerto, assim como os mecanismos moleculares que levam ao fenótipo. Nosso trabalho teve como objetivos principais a identificação de mutações no COL18A1 em um número maior de famílias com a SK, estabelecimento de novos protocolos que possam auxiliar no diagnóstico clínico e a avaliação do efeito funcional de variações encontradas na endostatina, domínio de maior conservação do colágeno XVIII. Propusemo-nos ainda a identificar proteínas que interagem com o domínio trombospondina. Apresentamos aqui a caracterização de sete novas mutações no colágeno XVIII em pacientes com SK, permitindo assim uma melhor determinação do espectro de variação fenotípica da SK. Com base na identificação dessas mutações pudemos incluir problemas neurológicos nos possíveis sinais clínicos presentes na SK ao apresentar pela primeira vez alterações de migração neuronal em pacientes com a síndrome. A ausência de mutações detectadas em três famílias sugere ainda a existência de heterogeneidade genética na SK. Também propomos neste trabalho a utilização da imunohistoquímica em biópsias de pele como teste diagnóstico para essa doença. Nossos resultados mostram também que a variação A48T da endostatina leva a alterações em sua interação com proteínas da matriz extracelular, enquanto a variação polimórfica D104N, previamente associada ao desenvolvimento de câncer de próstata, não leva a um efeito sobre a interação com as proteínas testadas. E, por último, o método de duplo híbrido não foi eficaz para a identificação de proteínas que possam interagir com o domínio trombospondina do colágeno XVIII. / Knobloch syndrome (KS) is an autosomal recessive disorder characterized by ophthalmological defects and presence of an occipital encephalocele. Clinical variability is present, however, all patients present high grade myopia, vitreoretinal degeneration and in most cases, retinal detachment; the occipital defect is also variable. Studies show that the KS is caused by mutations in COL18A1, the gene that codes for type XVIII collagen. This collagen is an extracellular matrix proteoglycan and has been the focus of a great number of studies due to its C-terminal domain, endostatin. Endostatin is a 20 kDa fragment that is proteolytically cleaved and possesses a high antiangiogenic activity. Type XVIII collagen is known to be expressed in three isoforms, different among themselves in the N-terminal region. These isoforms have distinct expression patterns, but are present in most basement membranes. Besides endostatin, type XVIII collagen also presents other domains with unknown functions: a thrombospondin domain, found in all isoforms; a frizzled domain, present in the longest isoform. The clinical variability spectrum in KS and the molecular mechanisms that lead to the phenotype are still uncertain. The aim of this study was to identify novel mutations in COL18A1 in additional KS families, to develop biochemical diagnostic tests that could allow the screening of a larger number of patients and to evaluate the effect of naturally found variants in the function of endostatin. We also performed a two-hybrid screening in order to identify proteins that can interact with the thrombospondin domain. The characterization of seven novel mutations in KS patients allowed us to better determine the clinical variability of KS. This work shows for the first time the presence of neuronal migration defects in some KS patients. The lack of detected pathogenic mutations in three families led us to propose the genetic heterogeneity of this syndrome. We demonstrate the possibility to use immunohistochemistry in skin biopsies as a diagnosis method. Our results also show the altered properties of T48 endostatin in its interaction with some extracellular matrix proteins. The N104 variant, that has been previously associated with prostate cancer, do not present any change in its interaction to the tested molecules. Finally, the two-hybrid system was not a good method to detect interacting proteins with the thrombospodin domain of collagen XVIII.